InGel Therapeutics, founded in 2021 and based in Cambridge, Massachusetts, is a biotechnology company specializing in stem cell-based therapies for retinal degenerative diseases. Their lead program, IGT001, aims to treat conditions like Retinitis Pigmentosa (RP) and Dry Age-Related Macular Degeneration (AMD). The therapy involves injecting purified rod photoreceptor precursors into the eye, which secrete protective exosomes to preserve cone-mediated vision. Preclinical studies in mice have shown promising results, and evaluations in larger animal models are underway.